department menu
Moorthy Palanki, Ph.D.

Moorthy Palanki, Ph.D.

Program Director, Professor of Practice in Biotechnology


Office: Extended Learning, Room 508

Moorthy Palanki, Ph.D.

Dr. Moorthy Palanki is the Director of the Undergraduate Degree Program in Biotechnology and Professor of Practice in Biotechnology.  Dr. Palanki is an accomplished Medicinal Chemist with extensive research experience in biotechnology and pharmaceutical industries. As a project manager, he led projects from inception to Phase I clinical trials in ocular, diabetes, cancer and neuroscience areas.  He has published numerous publications in scientific journals and obtain several patents.  While working at Celgene and TargeGen, he collaborated with CSUSM and other universities to develop internship programs and mentored students on a variety of research projects. 

At present, Dr. Palanki is teaching BA 670 The BioEntrepreneur: Science to Market in the PSM; BIOT257 Foundations of Biotechnology to undergraduate majors in biotechnology;  BIOT 450 Medical Biotechnology;  BIOT 397 Immersion iin Biotechnology; BIOT497, Internship in Biotechnology; and BIOT 457, Case Studies in Biotechnology.  He is actively involved with the local biotech communities.  He is a medicinal chemistry consultant for Tracon and Ivogen and a scientific board member for NovickBio.  

Education

Postdoctoral scholar at The Scripps Research institute in La Jolla in the lab of Professor Dale Boger, Ph.D.

Ph.D. in medicinal chemistry, The University Kansas, Lawrence, KS.                                                                    Thesis advisor Professor Gary Grunewald, Ph.D.,

M.Sc. Pharmaceutical Sciences, Madras University

B.Sc. Chemistry, Madras University

Research

Publications, Presentations and Patents 

  • Huang, J.; Ishino, T.; Chen, G.; Rolzin, P.; Osothprarop, T.; Retting, K.;  Li, L.; Jin, P.; Matin, M.; Huyghe, B.;  Talukdar, S.; Bradshaw, C.; Palanki, M.; Violand, B.; Woodnutt, G.; Lappe, R.; Ogilvie, K.; and Levin, N. Development of A Novel Long-acting Anti-diabetic FGF21 Mimetic by Targeted Conjugation to A Scaffold Antibody. Pharmacol. Exp. Ther. 2013, 346, 270
  • Palanki, M. S. S.; Bhat, A.; Bolanos, B.; Brunel, F.; Del Rosario, J.; Dettling, D.; Horn, M.; Lappe, R.; Preston, R.; Sievers, A.; Stankovic, N.; Woodnut, G.; Chen, G. Development of a long acting human growth hormone analog suitable for once a week dosing. Med. Chem. Lett. 2013, 23, 402.
  • Palanki, M. S. S.; Bhat, A.; Lappe, R. W.; Liu, B.; Oates, B.; Rizzo, J.; Stankovic, N.; Bradshaw, C. Development of novel linkers to conjugate pharmacophores to a carrier antibody. Med. Chem. Lett. 2012, 22, 4249.
  • Palanki, M. S. S.; Akiyama, H.; Campochiaro, P.; Cao, J.; Chow, C. P.; Dellamary, L.; Doukas, J.; Fine, R.; Gritzen, C.; Hood, J. D.; Hu, S.; Kachi, S.; Kang, X.; Klebansky, B.; Kousba, A.; Lohse, D.; Mak, C. C.; Martin, M.; McPherson, A.; Pathak, V. P.; Renick, J.; Soll, R.; Umeda, N.; Yee, S.; Yokoi, K.; Zeng, B.; Zhu, H.; Noronha, G. Development of Prodrug 4-Chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzo-triazin-7-yl)phenyl Benzoate (TG100801): A Topically Administered Therapeutic Candidate in Clinical Trials for the Treatment of Age-Related Macular Degeneration. Med. Chem. 2008, 51, 1546.
  • Palanki, M. S. S.; Dneprovskaia, E.; Doukas, J.; Fine, R. M.; Hood, J.; Kang, X.; Lohse, D.; Martin, M.; Noronha, G.; Soll, R. M.; Wrasidlo, W.; Yee, S.; Zhu, H. Discovery of 3,3'-(2,4-Diaminopteridine-6,7-diyl)diphenol as an Isozyme-Selective Inhibitor of PI3K for the Treatment of Ischemia Reperfusion Injury Associated with Myocardial Infarction.  Med. Chem., 2007, 50, 4279.
  • Cao, J.; Fine, R.; Gritzen, C.; Hood, J.; Kang, X.; Klebansky, B.; Lohse, D.; Mak, C. C.; McPherson, A.; Noronha, G.; Palanki, M. S. S.; Pathak, V. P.; Renick, J.; Soll, R.; Zeng, B.; Zhu, H. The design and preliminary structure-activity relationship studies of benzotriazines as potent inhibitors of Abl and Abl-T315I enzymes.  Med. Chem. Lett2007, 17, 5812.
  • Noronha, G.; Cao, J.; Chow, C.; Dneprovskaia, E.; Hwang, L.; Lohse, D.; Mak, C. C.; McPherson, A.; Fine, R. M.; Kang, X.; Klebansky, B.; Palanki, M. S. S.; Pathak, V. P.; Renick, J.; Soll, R.; Zeng, B. Targeting drug resistant mutations using novel binding interactions - lessons learned from Abl-T315I and their implications in drug design.  Frontiers in Drug Design and Discovery, 2007, 3, 121. 
  • Noronha, G.; Barrett, K.; Boccia, A.; Brodhag, T.; Cao, J.; Chow, C. P.; Dneprovskaia, E.; Doukas, J.; Fine, R.; Gong, X.; Gritzen, C.; Gu, H.; Hanna, E.; Hood, J. D.; Hu, S.; Kang, X.; Key, J.; Klebansky, B.; Kousba, A.; Li, G.; Lohse, D.; Mak, C. C.; McPherson, A.; Palanki, M. S. S.; Pathak, V. P.; Renick, J.; Shi, F.; Soll, R.; Splittgerber, U.; Stoughton, S.; Tang, S.; Yee, S.; Zeng, B.; Zhao, N.; Zhu, H. Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine-a potent, orally active Src kinase inhibitor with antitumor activity in preclinical assays Med. Chem. Lett. 2007, 17, 602
  • Fujimoto, H.; D'Alessandro-Gabazza, C. N.; Palanki, M. S. S.; Erdman, P. E.; Takagi, T.; Gabazza, E. C.; Bruno, N. E.; Yano, Y.; Hayashi, T.; Tamaki, S.; Simuda, Y.; Adachi, Y.; Suzuki, K.; Taguchi, O. Inhibition of nuclear factor-κB in T cells suppresses lung fibrosisAm J. Repir. Crit. Care Med. 2007, 176, 1251. 
  • Moore-Carrasco, R.; Busquets, S.; Almendro, V.; Palanki,  M. S. S.; Lopez-Soriano, F. J.; Argiles, J. M. The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. J. Oncol. 2007, 30, 1239.
  • Noronha, G.; Barrett, K.; Cao, J.; Dneprovskaia, E.; Fine, R.; Gong, X.; Gritzen, C.; Hood, J.; Kang, X.; Klebansky, B.; Lohse, D.; Mak, C. C.; McPherson, A.; Palanki, M. S. S.; Pathak, V. P.; Renick, J.; Soll, R.; Splittgerber, U.; Wrasidlo, W.; Zeng, B.; Zhao, N. Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors. Med. Chem. Lett. 2006, 16, 5546.
  • Palanki, M. S. S.; Erdman, P. E.; Ren, M.; Suto, M.; Bennett, B. L.; Manning, A.; Ransone, L.; Spooner, C.; Desai, S.; Ow, A.; Totsuka, R.; Tsao, P.; Toriumi, W. The Design and Synthesis of Novel Orally Active Inhibitors of AP-1 and NF-κB Mediated Transcriptional Activation. SAR of in vitro and in vivo  Bioorg. Med. Chem. Lett. 2003. 13, 4077.
  • Palanki, M. S. S.; Gayo-Fung, L. M.; Shevlin, G. I.; Erdman, P.; Sato, M.; Goldman, M.; Ransone, L. J.; Spooner, C. Structure-Activity Relationship Studies of Ethyl 2-(3-Methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)-pyrimidine-5-carboxylate: An Inhibitor of AP-1 and NF-κB Mediated Gene Expression. Med. Chem. Lett. 2002, 12, 2573.
  • Palanki, M. S. S. Inhibitors of AP-1, NF-κB and NFAT Mediated Transcriptional Activation: Therapeutic Potential in Autoimmune Diseases and Structural Diversity.  Med. Chem. 2002, 9, 219.
  • Palanki, M. S. S.; Erdman, P. E.; Gayo-Fung, L. M.; Shevlin, G. I.; Sullivan, R. W.; Suto, M. J.; Goldman, M. E.; Ransone, L. J.; Bennett, B. L.; Manning, A. M. Inhibitors of NF-kB and AP-1 Gene Expression: Structure-Activity Studies on the Pyrimidine Portion of 2-Chloro-4-trifluoromethyl Pyrimidine-5-[N-(3’,5’-bis(trifluoromethyl)phenyl]-carboxamide.  Med. Chem. 2000, 43, 3995.
  • Palanki, M. S. S.; Erdman, P. E.; Manning, A. M.; Ow, A.; Ransone, L. J.; Spooner, C.; Suto, C.; Suto, M. Novel Inhibitors of AP-1 and NF-kB Mediated Gene Expression: Structure-Activity Relationship Studies of Ethyl 4-[(3-methyl-2, 5-dioxo(3-pyrrolinyl))amino]-2-(trifluoromethyl)pyrimidine-5-carboxylate.  Med. Chem. Lett. 2000, 10, 1645.
  • Palanki, M. S. S.; Erdman, P. E.; Goldman, M. E.; Suto, C.; Suto, M. J. Synthesis and Structure-activity Relationship Studies of Conformationally Restricted Analogs of 2-Chloro-4-Trifluoromethylpyrimidine-5-[N  -(3’,5’-bis(trifluoromethyl)-phenyl)carboxamide.  Chem. Res. 2000, 10, 19.
  • Gerlag, D. M.; Ransone, L.; Tak, P. P.; Haz, Z.; Palanki, M. S. S.; Barbosa, M. S.; Boyle, D.; Manning, A. M.; Firestein, G. S. The effect of a T cell-specific NF-Kappa B inhibitor on in vitro cytokines production and collagen-induced arthritis.  Immunol. 2000, 165, 1652.
  • Palanki, M. S. S.; Manning, A. M. Interleukin-2 inhibitors in autoimmune disease.  Opin. Ther. Patents, 1999, 9, 27.
  • Suto, M. J.; Gayo-Fung, L. M.; Palanki, M. S. S.; Sullivan R. S. Solution-Phase Parallel Synthesis Using Ion-Exchange Resins. Tetrahedron, 1998, 54, 4141.
  • Sullivan, R. S.; Bigam, C. C.; Erdman, P. E.; Palanki, M. S. S.; Anderson, D. W.; Goldman, M. E.; Ransone, L. J.; Suto, M. J. 2-Chloro-4-(trifluoromethyl)pyrimidine-5-N-(3',5'-bis-(trifluoromethyl)phenyl)-carboxamide: A potent Inhibitor of NF-kB and AP-1 mediated Gene Expression Identified Using Solution-Phase Combinatorial Chemistry.  Med. Chem. 1998, 41, 413.
  • Jones, D. S.; Barstad, P. A.; Feild, M. J.; Hachmann J. P.; Hayag, M. S.; Hill, K. W.; Iverson, G. M.; Livingston, D. L.; Palanki, M. S. S.; Tibbetts, A. R.; Yu, L.; Coutts, S. M. Immunospecific Reduction of Antioligonucleotide Antibody-forming Cells with a Tetrakis-oligonucleotide Conjugate (LJP 394), a therapeutic Candidate for the Treatment of Lupus Nephritis. Med. Chem. 1995, 38, 2138.
  • Boger, D. L.; Johnson, D. S.; Palanki, M. S. S.; Kitos, P.; Chang, J.; Dowell, P. Evaluation of Functional Analogs of CC-1065 and the Duocarmycins Incorporating the cross-linking 9a-Chloromethyl-1,2,9,9a-tetra-hydrocyclopropa[c]benz[e]-indol-4-one (C2BI) Alkylation Subunit.  Med. Chem. 1993, 1, 27.
  • Boger, D. L.; Palanki, M. S. S. Functional Analogs of CC-1065 and the Duocarmycins Incorporating the 9a-Chloromethyl-1,2,9,9a-tetrahydrocyclo-propa-[c]benz[e]-indol-4-one (C2BI) Alkylation Subunit: Synthesis and Preliminary DNA Alkylation Studies. Am. Chem. Soc. 1992, 114, 9318.
  • Grunewald, G. L.; Palanki, M. S. S.; Vander Velde, D. Use of Transferred Nuclear Overhauser Effects to Determine the Conformation of 1-(3,4-Dichlorophenyl)-2-aminopropane when bound to the Active Site of Phenylethanolamine N-methyltransferase (PNMT).  Med. Chem. Lett. 1992, 2, 1681.
  • Grunewald, G. L.; Palanki, M. S. S.; Takusagawa, F. Structures of Two Conformationally Defined Phenylethanolamines: Exo-1,4-Epoxy-2-formamido-1,2,3,4-tetrahydro-8-trifluoro-methylnaphtha-lene and exo-1,4-Epoxy-2-formamido-1,2,3,4-tetrahydro-6-trifluoromethyl-naphthalene.  Acta Cryst. 1991, C47, 771.
  • Grunewald, G. L.; Kolar, A. J.; Palanki, M. S. S.; Paradkar, V. M.; Reitz, T. J.; Sall, D. J. One-Step Synthesis of Trifluoromethyl and of Methoxy-substituted Benzyne Precursors. Organic Preparations and Procedures International, 1990, 22, 747.

 

Oral and Poster PRESENTATIONS

  • Joselyn Del Rosario, Moorthy S.S. Palanki, Zemeda Ainekulu Michael Bacica, Lioudmila Campbell, Danielle Dettling, Kathryn Gropp, Mark Horn, Annette Sievers, Nebojsa Stankovic, Dean Wilkie, Abhijit Bhat, Rodney Lappe, Gary Woodnutt, Gang Chen. Development of Long-Acting Human Growth Hormone Suitable for Once a Week Dosing.  Poster No. MON-684.  Endo 2012, June 23-26, Houston, TX.
  • Bolanos, B.; Preston, R.; Palanki, M. MALDI-TOF In-Source Decay (ISD) for Characterization of Biotherapeutic Protein Conjugates. Poster. American Society for Mass Spectrometry Conference- 2012, Vancouver, BC, Canada.
  • Palanki, M. S. S. Development of Novel VEGF/Src inhibitor for the treatment of Age Related Macular Degeneration.  UC, Davis invited speaker.  May 30, 2012.
  • Palanki, M. S. S. TG100801: A Topically Administered Kinase Inhibitor for the Treatment of Age Related Macular Degeneration.  31st National Medicinal Chemistry Symposium, University of Pittsburgh, Pittsburgh, PA, June 15-19, 2008.
  • Palanki, M. S. S.; Cao, J.; Chen, Z.; Chow, C. P.; Dellamary, L.; Doukas, J.; Hood, J.; Lohse, D.; Mahesh, S.; Mak, C. C.; Martin, M.; McPherson, A.; Noronha, G.; Pathak, V. P.; Renick, J.; Soll, R.; Zeng, B. Development of a Src/VEGFr2 inhibitor for the potential treatment of age-related macular degeneration. 235th ACS National Meeting, New Orleans, LA, April 6-10, 2008.
  • McPherson, A.; Barker, G. E.; Cao, J.; Chow, C. P.; DeGuzman, R.; Dellamary, L.; McClure, D. E.; Mak, C. C.; Noronha, G.; Palanki, M. S. S.; Pathak, V. P.; Renick, J.; Soll, R.; Zeng, B. Strategies for the synthesis of the phase II clinical candidate TG100801. 235th ACS National Meeting, New Orleans, LA, April 6-10, 2008.
  • Mak, C. C.; Brown, J.; Cao, J.; Chen, Z.; Chow, C. P.; Dellamary, L.; Doukas, J.; Hood, J.; Kousba, A.; Lohse, D.; Mahesh, S.; Martin, M.; McPherson, A.; Noronha, G.; Olafson, T.; Palanki, M. S. S.; Pathak, V. P.; Racanelli-Layton, A.; Renick, J.; Soll, R.; Zeng, B. TG100801: A prodrug for the potential treatment of age-related macular degeneration (AMD). 235th ACS National Meeting, New Orleans, LA, April 6-10, 2008.
  • Cao, J.; Chow, C. P.; Dellamary, L.; Doukas, J.; Fine, R.; Hood, J.; Kang, X.; Klebansky, B.; Lohse, D.; Mak, C. C.; Martin, M.; McPherson, A.; Noronha, G.; Palanki, M. S. S.; Pathak, V. P.; Renick, J.; Soll, R.; Zeng, B. Discovery of TG100572, a dual VEGFr2/Src inhibitor, for the potential treatment of AMD. 235th ACS National Meeting, New Orleans, LA, April 6-10, 2008.
  • Palanki, M. S. S.; Cao, J.; Chow, C. P.; Dneprovskaia, E.; Fine, R.; Gritzen, C.; Kang, X.; Klebansky, B.; Mak, C. C.; McPherson, A.; Noronha, G.; Pathak, V. P.; Renick, J.; Soll, R.; Zeng, B.  A General Strategy for Designing Kinase Inhibitors by Structure Based Drug Design Targeting the Active Conformation - Lessons Learned from SRC and ABL-T315I.  8th Winter Conference of Medicinal and Bioorganic Chemistry, Steamboat Springs, Colorado, January 21-25, 2007.
  • Renick, J.; Zeng, B.; Cao, J.; Mak, C. C.; Chow, C.; McPherson, A.; Dneprovskaia, E.; Palanki, M. S. S.; Pathak, V.; Noronha, G.; Soll, R.; Lohse, D.; Zhu, H.; Hanna, E.; Hood, J.; Kang, X.; Klebansky, B.; Fine, R. Synthetic Strategies towards the Construction of Novel ABL- T315I Inhibitors.  41st Western Regional Meeting of the American Chemical Society, San Diego, California, October 9-13, 2007.
  • Zeng, B.; Cao, J.; Chow, C. P.; Mak, C. C.; Dneprovskaia, E.; Fine, R.; Gu, H.; Hanna, E.; Hood, J.; Kang, X.; Klebansky, B.; Li, G.; Lohse, D.; McPherson, A.; Noronha, G.; Renick, J.; Palanki, M. S. S.; Pathak, V. P.; Soll, R.; Tang, S.; Zhu, H. Strategies involved in the construction of two series of novel potent inhibitors of ABL-T315I.  234th ACS National Meeting, Boston, Massachusetts, August 19-23, 2007.
  • Chow, C. P.; Cao, J.; Dneprovskaia, E.; Fine, R.; Hanna, E.; Hood, J.; Hwang, L.; Kang, X.; Klebansky, B.; Lohse, D.; Mak, C. C.; McPherson, A.; Noronha, G.; Palanki, M. S. S.; Pathak, V. P.; Renick, J.; Soll, R.; Zeng, B.; Zhu, H. Design and SAR of thiazole-based inhibitors for the ABL-T315I enzyme.  234th ACS National Meeting, Boston, Massachusetts, August 19-23, 2007.
  • Dneprovskaia, E.; Cao, J.; Chow, C. P.; Fine, R.; Hanna, E.; Hood, J.; Kang, X.; Klebansky, B.; Lohse, D.; Mak, C. C.; McPherson, A.; Noronha, G.; Palanki, M. S. S.; Pathak, V. P.; Renick, J.; Soll, R.; Zeng, B.; Zhu, H. Design and SAR of pyrimidine-based inhibitors targeting the ABL-T315I mutation.  234th ACS National Meeting, Boston, Massachusetts, August 19-23, 2007.
  • Zhu, H.; Cao, J.; Chow, C.; Dneprovskaia, E.; Doukas, J.; Hanna, E.; Lohse, D.; Mak, C.; Martin, M.; McPherson, A.; Noronha, G.; Palanki, M. S. S.; Pathak, V. P.; Renick, J.; Soll, R.; Stoughton, S.; Tam, B.; White, R.; Yu, X.; Zeng, B.; Abramson, A.; Jamieson, C.; Hood, J. In vitro and in vivo Inhibition of the T315I Mutant BCR/ABL Kinase. 48th ASH annual Meeting and Exposition, Orlando, Florida, Dec 9-12, 2006.
  • Kovelman, R.; Palanki, M. S. S.; Cox, S.; Grimshaw, C. E.; O'Neill, J.; Motiwala, A.; Owens, S. R.; Pierce, S. W.; Martin, J. R.; Parnes, J. S.; Delgado, M.; Erdman, P.; Ezell, C.; Bennett, B.; Xu, W.; Xu, L. Control of the p38 Pathway with Small-Molecule Inhibitors of the Upstream Activators MKK3 and MKK6. Inflammation Research Association’s 11th National Conference, Bolton Landing, New York, October 6-10, 2002.
  • Palanki, M. S. S. Identification and Optimization of PKC-q Celgene Medicinal Chemistry Departmental Seminar, San Diego, California, July 9th 2002.
  • Palanki, M. S. S. NSP6783: A Compound for Treating Chemotherapy-Induced Neuropathy. Celgene Medicinal Chemistry Departmental Seminar, March, 2002, San Diego.
  • Palanki, M. S. S.; Erdman, P. E.; Ren, M.; Suto, M.; Bennett, B.; Manning, A.; Ransone, L.; Spooner, C.; Desai, S.; Ow, A.; Totsuka, R.; Tsao, P.; Toriumi, W.  The Design and Synthesis of a Novel Class of Quinazolines as Inhibitors of AP-1 and NF-kB Mediated Transcriptional Activation: SAR of in vitro and in vivo  XVIIth International Symposium on Medicinal Chemistry, Barcelona, Spain, September 1-5, 2002.
  • Erdman, P. E.; Suto, M.; Bennett, B. L.; Manning, A.; Ransone, L.; Spooner, C.; Desai, S.; Ow, A.; Ren, M.; Totsuka, R.; Tsao, P.; Toriumi, W.; Palanki M. S. S. Identification of an Orally Active Inhibitor of AP-1 and NF-kB mediated transcriptional Activation.  28th National Medicinal Chemistry Symposium, San Diego, California, June 8-12, 2002.
  • Shevlin, G. I.; Gayo-Fung, L. M.; Erdman, P. E.; Suto, M.; Goldman, M.; Ransone, L. J.; Spooner, C.; Palanki S. S. Structure-Activity Relationship Studies of Ethyl-2-[(3-Methyl-2,5-Dioxo(3-Pyrrolinyl))-Amino]-4-(Trifluoromethyl)-pyrimidine-5-Carboxylate, an Inhibitor of AP-1 and NF-kB Mediated gene Expression.  28th National Medicinal Chemistry Symposium, San Diego, California, June 8-12, 2002.
  • Palanki, M. S. S.; Erdman, P. E.; Suto, M. J.; Ransone, L. J.; Spooner, C.; Ow, A.; Manning, A. Inhibitors of NF-kB and AP-1 gene expression: Structure-activity Studies of Ethyl 2-Trifluoromethyl-pyrimidine-4-Citraconamide-5-Carboxylate. 26th National Medicinal Chemistry Symposium, Richmond, Virginia, June 14-18, 1998.
  • Palanki, M. S. S.; Erdman, P. E.; Gayo, L.; Shevlin, G.; Suto, M. J.; Ransone, L. J.; Goldman, M. E. Inhibitors of NF-kB and AP-1 gene expression: Structure-activity Studies on the pyrimidine portion of SP100030. 213th American Chemical Society National Meeting, San Francisco, April 13-17, 1997.
  • Erdman, P. E.; Palanki, M. S. S.; Suto, M. J.; Suto, C. M.; Goldman, M. E. Synthesis and Structure-activity relationship Studies of conformationally restricted analogs of SP100030, a potent inhibitor of NF-kB and AP-1 activation.  213th American Chemical Society National Meeting, San Francisco, California, April 13-17, 1997.
  • Palanki, S. S.; Boger, D. L. Synthesis of functional analogs of CC-1065 and the duocarmycins.  Fourth Annual Research symposium, The Scripps Research Institute, La Jolla, California, 1992.
  • Grunewald, G. L.; Palanki, M. S. S.; Vander Velde, D. Transferred nuclear Overhauser effect studies of the conformation of phenylethylamines and benzylamines when bound to the active site of phenylethanolamine N-methyltransferase.  The 1989 International Chemical Congress of Pacific Basin Societies, Honolulu, Hawaii, December 1989.
  • Palanki, M. S. S.; Wong, N.; Criscione, K.; Grunewald, G. L. Lipophilic requirements for the active site binding of substrates and inhibitors of phenylethanolamine N-methyltransferase. 23rd Midwest Regional Meeting of the American Chemical Society, Iowa City, Iowa, November, 1988.
  • Palanki, M. S. S.; Wong, N.; Criscione, K.; Grunewald, G. L. Conformationally defined analogs of norfenfluramine as probes for the active site of Phenylethanolamine N-methyltransferase.  25th Annual Medicinal Chemistry Meeting-in-Miniature, Lawrence, Kansas, April, 1987.

 

PATENTS

  • Anti-Diabetic Compounds. PCT/IB2012/057227.  US13/712,873, 2013
  • Ishino, T.; Palanki, M. S. S.; Violand, B.; Das, T.; Hodge, T.; Levin, N.; Parsons, E.  Anti-diabetic compounds comprising fibroblast growth factor FGF21 covalently attached to combining site of antibody with prepared linker.WO  2012059873.
  • Noronha, G.; Cao, J.; Chow, C.; Mak, C. C.; Palanki, M.; Dneprovskaia, E.; Mcpherson, A.; Pathak, V.; Renick, J. Preparation of alkynyl pyrrolopyrimidine compounds as JAK kinase inhibitors. WO2009055674.
  • Noronha, G.; Cao, J.; Chow, C. P.; Mak, C. C.; Palanki, M. S. S.; Dneprovskaia, E.; McPherson, A.; Pathak, V.; Renick, J.; Zeng, B. Preparation of pyrrolopyrimidine compounds and their use as janus kinase modulators. WO 2009049028.
  • Cao, J.; Chow, C.; Mak, C. C.; Noronha, G.; Palanki, M. S. S. Thiazolidine compounds, and methods of making and using same. WO20090226.
  • Cao, J.; Hood, J.; Lohse, D.; Mak, C. C.; McPherson, A.; Noronha, G.; Pathak, V.; Renick, J.; Soll, R. M.; Zeng, B.; Chow, C.; Palanki, M. S. S.; Dneprovskaia, E. Preparation of six membered heteroaromatic, particularly pyrimidine and triazine, inhibitors targeting resistant kinase mutations for treating angiogenic and hematological associated disorders.  WO 2007056075.
  • Cao, J.; Hood, J.; Lohse, D.; Mak, C. C.; McPherson, A.; Noronha, G.; Pathak, V.; Renick, J.; Soll, R. M.; Zeng, B.; Chow, C.; Palanki, M. S. S.; Dneprovskaia, E. Thiazoles as inhibitors targeting resistant and kinase mutations and their preparation and use in the treatment of angiogenic-associated or hematological disorders.  WO 2007056023.       
  • Albers, R.; Ayala, L.; Clareen, S. S.; Delgado, M.; Hilgraf, R.; Hedge, S.; Hughes, K.; Kois, A.; Plantevin-Krenitsky, V.; McCarrick, M.; Nadolny, L.; Palanki, M. S. S.; Sahasrabudhe, K.; Sapienza, J.; Satoh, Y.; Sloss, M.; Sudbeck, E.; Wright, J.  Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith.
  • Baudler, M.; Bhagwat, S. S.; Erdman, P. E.; Gantner, F.; Palanki, M. S. S.; Schudt, C.; Stadlwieser, J.; Zapf, J. Preparation of substituted diaminopyrimidines as protein kinase C-q inhibitors. WO2003106451.
  • Kois, A.; MacFarlane, K. J.; Satoh, Y.; Bhagwat, S. S.; Parnes, J. S.; Palanki, M. S. S.; Erdman, P. E. Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto.  WO0246171, US20030203926.
  • Kois, A.; MacFarlane, K. J.; Satoh, Y.; Bhagwat, S. S.; Parnes, J. S.; Palanki, M. S. S.; Erdman, P. E. Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto. WO0246170.
  • Palanki, M. S. S.; Bhagwat S.; Sato, H.; Erdman, P.; Doubleday, M. Neuroprotective agents and methods related thereto. US6,399,606.
  • Bhagwat, S.; Palanki, M.; Erdman, P.; Doubleday, M.; Sato, H. Neuroprotective agents and methods related thereto. WO0140187.
  • Palanki, M. S. S.; Suto, M. J. Pyridopyramidine analogs and related compounds and methods for treating inflammatory conditions.  US6150372.
  • Palanki, M. S. S.; Suto, M. J. Preparation of quinazoline analogs and related compounds for treating inflammatory conditions.  WO9901441, US5949421.
  • Suto, M. J.; Gayo, L. M.; Palanki, M. S. S.; Ransone-Fong, L. J. Preparation of pyrimidinecarboxylates and analogs as transcription factor activation inhibitors.  US5935966, WO9838171. 
  • Suto, M. J.; Goldman, M. E.; Gayo, L. M.; Ransone-Fong, L. J.; Palanki, M. S. S.; Sullivan, R. W. Preparation of pyrimidinecarboxamides and pyrazinecarboxamides for treating inflammatory conditions. WO9709315, US5811428.
  • Suto, M. J.; Gayo, L. M.; Palanki, M. S. S.; Ransone-Fong, L. J. Preparation of pyrimidinecarboxylates and related compounds for treating inflammatory conditions.  WO9709325, US5852028.

Courses

BA 670 - The Bioentrepreneur: Science to Market

BIOL 596 - Adv Topics in Current Biological Research

BIOT 357 - Foundations of Biotechnology

BIOT 497 -  Biotechnology Internship

BIOT 457 - Case Studies in Biotechnology Product Development

CHEM201 - Organic Chemistry I 

CHEM201L - Organic Chemistry I Lab

CHEM202L - Organic Chemisty II Lab

CHEM150L - General Chemistry Lab

Vitae

Tracon Pharmaceuticals, Inc, San Diego, CA                                                      2015 - Present

Medicinal Chemistry Consultant

Providing chemistry and medicinal chemistry research project services.

 

Ivogen, Inc., Columbia, MO                                                                                         2016 - Present

Medicinal Chemistry Consultant

Providing chemistry and medicinal chemistry research project services.

 

Retrophin, Inc, San Diego, CA                                                                                        2014 - 2015

Director of Medicinal Chemistry

Retrophin is a biopharmaceutical company focused on discovering, developing and marketing innovative therapies for debilitating and often life-threatening rare diseases.

 

Pfizer, San Diego, CA                                                                                                       2008 - 2013

Senior Principal Scientist

Led a multi-disciplinary team of scientists to advance projects to Phase I.   Hands on experience in antibody-protein-peptide conjugates as well as antibody small molecule conjugates

  • R & D Project Lead for two anti-diabetic projects. Advanced novel antibody-FGF21 conjugate (CVX-343) for diabetes to Phase I trial.  
  • Produced a first-in-class bi-functional therapeutic antibody-peptide-FGF21 (CVX-478) for diabetes and weight loss that was advanced to CAN stage with in 12 months. 
  • Led the development of a long-acting human growth hormone compound (conjugate of an antibody with a protein using small molecule) for weekly dosing from idea through to candidate nomination stage within 15 months with very limited resources. 
  • Managed and directed chemistry projects at CROs in Germany, India and China.

TARGEGEN, Inc.  San Diego, CA                                                                                        2006 - 2008

Principal Scientist IV

Advanced projects to Phase I by working with M.S. and Ph.D. level scientists on oncology area.

  • Advanced TG100801, a kinase inhibitor, as a topical treatment for age-related macular degeneration to Phase I trial. This was a first in class small molecule topical ocular compound for treating age-related macular degeneration. The compound was acquired by Sanofi.   
  • Developed small molecule kinase inhibitors targeting JAK2 and PI3K kinases for oncology indications.
  • Worked with director of chemistry and developed and managed portfolio of projects. Planned the project activities, outlined goals and provided updates to management.

CELGENE, San Diego, CA                                                                                                  1994 – 2006

Group Leader

Managed scientists, provided scientific expertise and researched direction for new and ongoing projects. 

  • Created and managed several teams, including hiring and training, to provide cohesive operations:
    • Head of Library Generation Group: Led team of four scientists and designed and synthesized novel chemical libraries for internal drug discovery targets. 
    • Head of Compound Library Management and Distribution group that acquired novel compounds, plated them and distributed to various projects. Implemented bar-code system that tracked inventory and distribution which reduced errors to 0%.  Acquired and managed 200,000 compounds in house.  Managed budget, facilitated decisions, and reached goals in timely manner.
    • Head of Analytical Chemistry Group that supported Medicinal Chemistry for determination of compound purity, solubility, and serum stability. Trained sub-teams on new assays.   

Senior Scientist I

Advanced projects Phase 1 by working with a team of chemists and biologists in oncology and inflammation.

Project Leader

  • Developed SPC0120578 for inflammatory indication by targeting PKC-q kinase, and advanced the compound to Phase I clinical trials.  Completed in a year with 2 chemists and 3 biologists.  This compound was licensed to Byk-Gulden   
  • Received Outstanding Achievement Award for leading and completing PKC-q
  • As a project lead, developed NSP6783 for chemotherapy induced neuropathy, a novel compound that promoted nerve growth, and advanced to Phase I clinical trial.  Achieved project goals.  This project was completed within 2 years with four chemists and 8 biologists.  This compound was licensed to Nippon-Kayaku
  • Received most Valuable Player Award for leading and completing all the goals of Neuroprotectant Project on time.

Senior Chemist

  • For IKK2 project, developed AS2868 for inflammatory indication advanced to in vivo stage, and licensed to Received Outstanding Achievement Award for developing an inhibitor for IKK2.
  • For Inflammation project, developed SP100393 targeting AP-1 and NF-kB transcriptional factors as anti-inflammatory compound with improved oral PK properties and efficacy.  Achieved project goal and compound was licensed to Tanabe.  Honored with ‘Team of the Year’ Award, NF-kB Project Team.    

Custom Tab 1

Custom Tab 2